Given the results from the COHERE study (mean decline in CD4 count in the year before diagnosis of Hodgkin lymphoma in virologically suppressed patients reciving HAART was 98 cells/μl) [13] and other recent data from Italy showing a mean CD4 count decline of 99 cells/μl in the year before diagnosis of Hodgkin lymphoma, compared with a mean increase of 37 cells/μl in controls [7], it might be inferred that an opportunity will be missed to make the diagnosis. The gene discussed is CD4; the disease is Hodgkins lymphoma.